Search Results



Your search for Alice Goodman matches 635 pages

Showing 51 - 100


supportive care

Expert Point of View: Richard L. Schilsky, MD, and Don Dizon, MD

“[THE STREAM, Conquer Fear, and CALM] studies focus on the psychosocial aspects of coping with cancer. One theme that binds them is that oncologists take pride in the fact that we treat people with cancer [with the emphasis on people] and care for them, their caregivers, and their support...

supportive care

Brief Psychological Interventions Positively Affect Cancer Patients’ Well-Being

Three separate brief psychological interventions aimed at helping cancer patients cope with distress have shown improvements in quality of life and well-being across the continuum of cancer care. The interventions were studied—respectively—in newly diagnosed cancer patients, survivors after cancer...

hematologic malignancies
leukemia

Idelalisib Toxicities Appear to Be Immune-Related

Phosphoinositide 3-kinase (PI3K) inhibitors represent a highly active class of drug for the treatment of chronic lymphocytic leukemia (CLL). Idelalisib (Zydelig), a PI3K-delta inhibitor and the first PI3K inhibitor to be approved by the U.S. Food and Drug Administration (FDA) for CLL, has...

leukemia

Venetoclax Achieves Durable and Deep Remissions in CLL

Preliminary study results suggest that venetoclax (Venclexta) plus rituximab (Rituxan) is a highly active combination in relapsed/refractory chronic lymphocytic leukemia (CLL), achieving durable responses and minimal residual disease negativity in previously treated patients. “The results of our...

lung cancer

Expert Point of View: Trever Bivona, MD, PhD

“The results of this trial are promising but need to be reproduced in the United States and other countries before clear recommendations can be made. There are adjuvant studies such as ALCHEMIST underway to test this strategy in U.S. patients,” said Trever Bivona, MD, PhD, Associate Professor of...

lung cancer

Adjuvant Gefitinib Delays Recurrence in EGFR-Positive NSCLC

Adjuvant therapy with gefitinib (Iressa), an epidermal growth factor receptor (EGFR)-targeted agent, was more successful at preventing recurrence than standard-of-care chemotherapy, in a phase III study of patients with EGFR-positive non–small cell lung cancer (NSCLC).1 Gefitinib extended...

skin cancer

New Immunotherapy Combinations Gain Ground in Advanced Melanoma, but Results Preliminary

Attention is focused among the cancer community on identifying the optimal immunotherapy combinations, with more than 800 ongoing trials of combination therapy. Two studies presented at the 2017 Annual Meeting of the American Association for Cancer Research (AACR) reported promising preliminary...

leukemia

Expert Point of View: David L. Porter, MD & Jonathan S. Serody, MD

In a separate interview with The ASCO Post, David L. Porter, MD, Director of Blood and Marrow Transplantation and the Jodi Fisher Horowitz Professor in Leukemia Care Excellence at the University of Pennsylvania, Philadelphia, said: “It is encouraging that many patients with acute lymphoblastic...

leukemia

CAR T Cells in Relapsed B-Cell Acute Lymphoblastic Leukemia

Updated results in 51 adults with relapsed B-cell acute lymphoblastic leukemia (ALL) treated with chimeric antigen receptor (CAR) T cells at Memorial Sloan Kettering Cancer Center in New York showed high complete response rates regardless of pre–CAR T disease burden.1 That said, pretreatment...

breast cancer

Expert Point of View: Aditya Bardia, MD, MPH

Commenting on the phase I study of atezolizumab (Tecentriq) presented at the 2017 American Association for Cancer Research Annual Meeting, Aditya Bardia, MD, MPH, Attending Physician at Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, said: “It is very encouraging to...

breast cancer

Atezolizumab Improves Overall Survival in Small Subset of Patients With Triple‑Negative Breast Cancer

Triple-negative breast cancer is an aggressive disease with no approved targeted therapy, and it remains challenging to treat. Early data from a phase I study suggest that the PD-L1 inhibitor atezolizumab (Tecentriq) can extend the lives of a subset of women who respond to this checkpoint...

breast cancer

Expert Point of View: Filipa Lynce, MD

Formal discussant of the MONARCH 1 trial and the MONALEESA-2 biomarker analysis, Filipa Lynce, MD, of Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, noted that this is the first study to evaluate a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor in patients with progressive...

breast cancer

Abemaciclib Active in Metastatic Breast Cancer

In the single-arm phase II MONARCH 1 trial, the investigational cyclin-dependent kinase 4/6 (CDK4/6) inhibitor abemaciclib achieved an objective response in about 20% of heavily pretreated patients with metastatic hormone receptor–positive, HER2-negative breast cancer and a disease control rate of...

hematologic malignancies
breast cancer
lung cancer
kidney cancer
sarcoma
bladder cancer
colorectal cancer
multiple myeloma
genomics/genetics

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): 2017 Guidelines

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): 2017 Guidelines In 1996, the National Comprehensive Cancer Network® (NCCN®) published its first set of Clinical Practice Guidelines in Oncology®, covering 8 tumor types. Guidelines are now published for more than 60 tumor types and...

hepatobiliary cancer

Expert Point of View: Lipika Goyal, MD

Commenting on the BILCAP study, Lipika Goyal, MD, an oncologist at Massachusetts General Hospital, Boston, said: “These results are very intriguing. There is no current standard of care for adjuvant therapy of biliary tract cancer. Our high-risk patients [ie, patients with node-positive disease,...

hepatobiliary cancer

Adjuvant Capecitabine for Biliary Tract Cancer Yields Significant Improvement in Overall Survival

There is no standard adjuvant therapy for patients with resectable biliary tract cancer, but that may be about to change based on results of the phase III BILCAP trial.1 Adjuvant capecitabine significantly improved overall survival in the BILCAP trial, and this is the first study to show a benefit...

lung cancer

Expert Point of View: Ashish Saxena, MD, PhD

After the data were presented, Ashish Saxena, MD, PhD, Assistant Professor of Medicine at Weill Cornell Medical College and Assistant Attending Physician at the NewYork-Presbyterian Hospital, New York, weighed in on the CA209-003 study. “The results of this trial are exciting and give hope to...

lung cancer

Five-Year Survival Quadrupled in Responders to Immunotherapy for Non–Small Cell Lung Cancer

At 5 years, the overall survival rate was 16% in patients with advanced non–small cell lung cancer (NSCLC) treated with single-agent nivolumab (Opdivo), according to follow-up of a phase Ib dose-ranging study (CA209-003), presented at the American Association for Cancer Research (AACR) Annual...

skin cancer

Expert Point of View: Gary K. Schwartz, MD

Gary K. Schwartz, MD, Chief of Hematology/Oncology and Deputy Director of the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian/Columbia University Medical Center, New York, is not sold on using the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for all patients with...

skin cancer

Nivolumab/Ipilimumab Combination Improves Survival Over Ipilimumab Alone in Patients With Melanoma

The race is on to identify combinations of immune checkpoint inhibitors that can improve outcomes over the use of immune checkpoint inhibitor monotherapy. Updated results of the phase III CheckMate 067 trial found the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) improved survival in...

cns cancers

One Physician’s Experience

In a separate interview, George Ansstas, MD, a medical neuro-oncologist at Siteman Cancer Center, Washington University, St. Louis, discussed his experience in treating patients with tumor-treating fields. He has treated about 35 patients with glioblastoma in the first-line setting and 20 with...

cns cancers

Expert Point of View: George Demetri, MD

“I am intrigued by this study. I have no idea by which molecular mechanism this [tumor-treating fields therapy] works, but the data are the data,” said George Demetri, MD, of Dana-Farber Cancer Center, Boston. Dr. Demetri moderated the press conference where these data were discussed. “A panoply...

cns cancers

‘Out-of-the-Box’ Approach Plus Temozolomide Extends Survival in Glioblastoma

Using a novel approach called tumor-treating fields—which involves the delivery of low-intensity electric fields to the brain by a patient-operated device—along with standard-of-care temozolomide therapy improved overall survival and progression-free survival vs temozolomide alone in patients with...

leukemia

Expert Point of View: Susan O'Brien, MD

Susan O’Brien, MD, Associate Director for Clinical Science, Chao Family Comprehensive Cancer Center, University of California Irvine Health, put the venetoclax (Venclexta) monotherapy study in context. “The study by Jones et al is impressive. Patients who fail on a prior kinase...

leukemia

Updated Data on Treatment With Ibrutinib and Venetoclax in Patients With CLL/SLL

Long-term follow-up of treatment with ibrutinib (Imbruvica) in patients with previously untreated and treated chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) has shown high response rates that are durable. At 5 years, 89% of patients with treatment-naive and relapsed or...

kidney cancer

Expert Point of View: Eric Jonasch, MD

Eric Jonasch, MD, Professor in the Department of Genitourinary Cancer at MD Anderson Cancer Center in Houston, commented on this phase II study. “This is an important study, since we have, for the first time, randomized, prospective data comparing the combination of a checkpoint antibody with an...

kidney cancer

Combination of Atezolizumab and Bevacizumab in PD-L1–Positive Patients With Metastatic Kidney Cancer

The combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) appears to be promising in the first-line treatment of patients with metastatic renal cell carcinoma, according to results of a phase II trial presented at the 2017 Genitourinary Cancers Symposium.1 Despite the failure of the...

solid tumors

Expert Point of View: Prof. Noel Clarke, MBBS, FRCS, ChM

Formal discussant of the 111 trial, Prof. Noel Clarke, MBBS, FRCS, ChM, The Christie Hospital, Manchester, UK, had some concerns, but overall felt that the study could be practice-changing. “In this paper, single-cycle treatment is safe and effective, and two cycles of adjuvant BEP (bleomycin,...

solid tumors

One Cycle of BEP as Good as Two in High-Risk Testicular Cancer

The approach to treatment of high-risk, clinical stage I, nonseminomatous or combined germ cell tumors of the testis is not written in stone. ­Orchiectomy followed by surveillance or chemotherapy with two cycles of bleomycin, etoposide, and cisplatin (BEP) is a favored approach by most experts. A...

prostate cancer

Progress in Defining Molecular Signature for Aggressive Androgen-Indifferent Prostate Cancer

Prostate cancer has lagged behind breast cancer in the identification of predictive and prognostic biomarkers, but the field is catching up. Researchers have identified a molecular signature that can distinguish aggressive prostate cancer that is androgen-indifferent and will have a better response ...

skin cancer

Expert Point of View: Suzanne L. Topalian, MD

“Avelumab (Bavencio) is the very first drug approved for Merkel cell carcinoma, an orphan disease that is uncommon in the United States. For that reason, pharmacologic development has been slow. In this case, laboratory evidence provided a rationale for testing checkpoint inhibitors in Merkel cell ...

skin cancer

Avelumab Produces Durable Responses in Merkel Cell Carcinoma, Becomes First Drug Approved for the Rare Disease

Avelumab (Bavencio) achieved durable responses in patients with metastatic Merkel cell carcinoma, according to longer-term follow-up of the phase II JAVELIN study, the largest study conducted to date in this relatively rare orphan cancer.1 Results were presented at the 2017 American Association for ...

AACR Introduces New Incoming Officers of the Associate Member Council

The American Association for Cancer Research (AACR) issued congratulations to Allison S. Betof, MD, PhD, on her election to Chairperson-elect of the Associate Member Council (AMC) of AACR. Dr. Betof assumed office at the AACR Annual Meeting earlier this month and will serve as Chairperson-elect...

colorectal cancer

Expert Point of View: Rodrigo Dienstmann, MD

“This is one of the most beautiful stories we have in translational precision oncology research in colorectal cancer. We have robust preclinical data, rigorous molecular diagnosis, and successful clinical results,” said formal discussant of this trial, Rodrigo Dienstmann, MD, of Vall D’Hebron...

colorectal cancer

Dual HER2 Targeting of HER2-Positive Metastatic Colorectal Cancer Shows Clinical Benefit

The combination of trastuzumab (Herceptin) plus lapatinib (Tykerb) achieved positive results in patients with heavily pretreated, HER2-positive metastatic colorectal cancer, according to the final results of the phase II HERACLES-A trial. This two-pronged, HER2-directed approach achieved clinical...

kidney cancer

Cryoablation for Small Renal Tumors: One Radiologist’s Experience

In a separate talk at the 2017 Genitourinary Cancers Symposium, Thomas Atwell, MD, a radiologist at the Mayo Clinic, Rochester, Minnesota, who performs ablation, discussed his experience with cryoablation for small renal tumors. “Early in our practice, we used both radiofrequency ablation and...

kidney cancer

Expert Point of View: Alessandro Volpe, MD

Formal discussant of this abstract, Alessandro Volpe, MD, of the University of Eastern Piedmont Hospital, Maggiore Della Carita Hospital, Novara, Italy, commented that nephron-sparing surgery is recommended for clinical stage T1 tumors; however, when compared with ablation, the advantages of...

kidney cancer

Evolving Role for Cryoablation in Treating Small Renal Masses

Selected “healthy” patients with clinical T1 renal cell carcinoma may be safely treated with percutaneous cryoablation, according to a single-center study of experience at the Mayo Clinic.1 “In healthier patients, our experience shows that cryoablation achieved good short-term oncologic control...

prostate cancer

Expert Point of View: Joseph Greer, PhD

“These data are consistent with other studies we have conducted in advanced lung cancer, in which we similarly found that one-third of patients believed that their metastatic lung cancer was curable. These patients ostensibly already had conversations with their oncologists about their prognosis...

prostate cancer

Aligning Patient Expectations With Treatment Goals in the Metastatic Setting

More than one-third of men with incurable metastatic prostate cancer mistakenly believe that their cancer may be curable, according to a survey of patient expectations at an academic cancer center. “This study is part of a larger survey of treatment decision-making among men with metastatic...

kidney cancer

Active Surveillance Appears to Be Safe for Small Renal Masses

The prospective Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) registry shows that over the intermediate term, active surveillance appears to be as safe as primary intervention for carefully selected, older, sicker patients with small renal masses.1 As the data mature,...

cost of care

Value-Based Approaches to the Rising Costs of Cancer Drugs

It’s no secret that cancer drug costs have skyrocketed out of control, with some treatments costing as much as $100,000 to $200,000 per year and even upward. This has put tremendous strain on the U.S. health-care system, while causing financial toxicity and bankruptcy for many patients. Peter B....

hematologic malignancies

Expert Point of View: Selina Luger, MD, Stephanie Lee, MD, and Gabriela Hobbs, MD

Speaking at the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition, before the hold on pacritinib was lifted (in January 2017), Selina Luger, MD, of the University of Pennsylvania, Philadelphia, commented, “I think the U.S. Food and Drug Administration (FDA) needs to revisit ...

hematologic malignancies

Pacritinib Reduces Spleen Volume in Myelofibrosis

The investigational drug pacritinib met the primary endpoint of the phase III PERSIST-2 trial in high-risk patients with myelofibrosis and thrombocytopenia. Treatment with the Janus kinase (JAK)1/2 inhibitor pacritinib achieved a significant reduction in spleen volume compared with best available...

prostate cancer

Expert Point of View: Susan F. Slovin, MD, PhD

Formal discussant for the presentation of SWOG S9921 results, Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, New York, said there were some important points to understand about this “vintage” trial.  “The trial was designed 20 years ago, and the view is...

prostate cancer

No Benefit From Older Standard-of-Care Drug in Adjuvant Chemotherapy for High-Risk Prostate Cancer, but Newer Trials Feasible

An older trial designed to evaluate the benefits of adjuvant therapy following radical prostatectomy in patients with high-risk prostate cancer showed no difference in overall or disease-free survival between 2 years of androgen-deprivation therapy and 2 years of androgen-deprivation therapy plus...

bladder cancer

Phase II Trial Evaluates New Gene Therapy for Non–Muscle Invasive Bladder Cancer After BCG

A novel approach using intravesical gene therapy showed promising activity in a phase II trial that enrolled patients with bacillus Calmette-Guérin (BCG)-refractory or -relapsed nonmuscle invasive bladder cancer.1 The rate of high-grade relapse-free survival at 12 months was 35% in patients treated ...

breast cancer

New Data on Prognostic Factors, Disease Detection, Drug Toxicities, and Treatment Adherence Presented at SABCS

The San Antonio Breast Cancer Symposium (SABCS) offers state-of-the-art information on all aspects of breast cancer biology, diagnosis, and treatment, drawing an international audience of more than 7,500 physicians, researchers, and other health-care professionals from over 90 countries. Through...

prostate cancer

On the Horizon: New Tools for Prostate Cancer

The field of prostate cancer is being energized by discoveries in genetics, novel imaging techniques, and the potential of checkpoint inhibitors in the treatment of prostate cancer. Not all of these advances are currently clinically actionable, but all have the potential to change clinical...

breast cancer

Expert Point of View: Amber Orman, MD

Amber Orman, MD, of the Department of Radiation Oncology, Breast Section, at Moffitt Cancer Center in Tampa, Florida, who was not involved in this study, said: “This study provides guidance when deciding how best to integrate postmastectomy reconstruction and radiation therapy. This is an area...

Advertisement



Advertisement


Advertisement